Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jun 16:10:178.
doi: 10.1186/s13256-016-0969-5.

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

C Baudon  1   2 , F P Duhoux  3   4 , I Sinapi  3 , J L Canon  3
Affiliations
Case Reports

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

C Baudon et al. J Med Case Rep. .

Abstract

Background: Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab and pertuzumab combination therapy. Knowledge of risk factors and active prevention proceedings is of utmost importance to avoid fatal outcomes.

Case presentation: We present the case of a chemo-naive 58-year-old Belgian woman developing hypovolemic shock and multiple organ failure due to tumor lysis syndrome after a single dose of trastuzumab and pertuzumab in the context of the treatment of a metastatic breast cancer and resulting in fatal outcome despite optimal management.

Conclusions: Considering that targeted cancer therapies become increasingly effective, oncologists should be extremely cautious when treating patients at high risk of tumor lysis syndrome, even if they are not treated with cytotoxic chemotherapy, and determine appropriate prophylaxis.

Keywords: Pertuzumab; Solid tumor; Trastuzumab; Tumor lysis syndrome.

PubMed Disclaimer

References

    1. Mott FE, Esana A, Chakmakjian C, et al. Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005;2:188–91. doi: 10.3816/SCT.2005.n.012. - DOI - PubMed
    1. Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11. doi: 10.1111/j.1365-2141.2004.05094.x. - DOI - PubMed
    1. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: an expert panel consensus. Br J Haematol. 2010;149:578–86. doi: 10.1111/j.1365-2141.2010.08143.x. - DOI - PubMed
    1. Mirrakhimov AE, Voore P, Khan M, et al. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4(2):130–8. doi: 10.5492/wjccm.v4.i2.130. - DOI - PMC - PubMed
    1. Vodopivec DM, Rubio JE, Fornoni A et al. An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. Case Rep Med. 2012(2012):468452. - PMC - PubMed

Publication types

MeSH terms